In a murine model of hypercholesterolemia expressing human PCSK9, FAP2M21 showed similar efficacy and potency than alirocumab, a result that was not trivial since the former binds the module 2 (amino acids 530-605) of the C-terminal domain (CTD) of PCSK9, while alirocumab blocks the interaction between the catalytic domain of PCSK9 and the EGF-A of the LDL receptor. Here, PCSK9 is linked to Hypercholesterolemia.